Advertisement

Topics

Kyowa Hakko, USA Inc. Company Profile

16:18 EST 17th November 2017 | BioPortfolio


News Articles [83 Associated News Articles listed on BioPortfolio]

Kyowa Hakko Kirin and Kyowa Kirin International Announce Burosumab Data Presentations at ASBMR 2017 Annual Meeting

TOKYO and LONDON, August 24, 2017 /PRNewswire/ -- Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) and Kyowa Kirin International PLC (Kyowa Kirin International), a wholly owned subsidiary of Kyowa ...

Kyowa Hakko Kirin Announces Marketing Authorisation Application for Mogamulizumab Validated by ...

Kyowa Hakko Kirin Co. Ltd.MediaHiroki Nakamura, +81-3-5205-7205media@kyowa-kirin.co.jp Read more...

Kyowa Hakko Kirin gibt von der Europäischen Arzneimittelagentur verifizierten Vermarktungszulassungsantrag für Mogamulizumab bekannt

Tokio (ots/PRNewswire) - Die Kyowa Hakko Kirin Co., Ltd. (Tokio: 4151 President und CEO: Nobuo Hanai, "Kyowa Hakko Kirin" gibt heute bekannt, dass ihr Vermarktungszulassungsantrag (MAA) für Mogamul.....

Kyowa Hakko drops development of tivantinib

Japanese drugmaker Kyowa Hakko Kirin says it has discontinued the development of tivantinib (ARQ: 197),…

Kyowa Hakko Kirin Co., Ltd.: US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the Treatment of Mycosis Fungoides and Sézary Syndrome

Friday, August 25th 2017 at 6:30am UTC TOKYO–(BUSINESS WIRE)– Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151)(President and CEO: Nobuo Hanai, “Kyowa Hakko Kirin”) today announced that U.S. Fo...

Kyowa Hakko Kirin Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 13062017] Prices from USD $350

Kyowa Hakko Kirin Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Kyowa Hakko Kirin Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances an...

Kyowa's mogamulizumab granted breakthrough therapy status

Kyowa Hakko Kirin's mogamulizumab, indicated for the treatment of mycosis fungoides and Sezary syndrome, was granted breakthr -More- 

Kyowa Kirin and Ultragenyx to proceed with US regulatory bid for burosumab

Shares in Japan’s Kyowa Hakko Kirin are up nearly 4% following news that the company will proceed next…

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [11 Associated Companies listed on BioPortfolio]

Kyowa Pharmaceutical, Inc

From its foundation in 1949, Kyowa Hakko has been a global leader in the pharmaceutical industry. Today, Kyowa's expertise extends to the United States through Kyowa Pharmaceutical, Inc. headquartered...

Kyowa Hakko, USA Inc.

Kyowa Hakko

Kyowa Hakko USA

Kyowa Hakko Kirin Co., Ltd.

More Information about "Kyowa Hakko, USA Inc." on BioPortfolio

We have published hundreds of Kyowa Hakko, USA Inc. news stories on BioPortfolio along with dozens of Kyowa Hakko, USA Inc. Clinical Trials and PubMed Articles about Kyowa Hakko, USA Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kyowa Hakko, USA Inc. Companies in our database. You can also find out about relevant Kyowa Hakko, USA Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record